Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Morschhauser

Showing results (61-70 of 272) with videos related to

Pageof 28
Sort By:
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Blood Cancer Journal|August 21, 2021
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trialFranck Morschhauser, Nilanjan Ghosh, Izidore S Lossos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Hematology & Oncology|September 19, 2024
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patientsMarion Alcantara, Marion Chevrier, Fabrice Jardin, et al.
Blood Advances|April 20, 2021
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphomaCédric Ménard, Delphine Rossille, Joelle Dulong, et al.
Haematologica|January 16, 2016
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient ProgramAurore Perrot, Hélène Monjanel, Réda Bouabdallah, et al.
Blood|August 22, 2014
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN studyGuillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, et al.
Hematological Oncology|December 1, 2024
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I TrialAnna Sureda, Antonio Pinto, Hervé Ghesquières, et al.
Blood|March 28, 2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser, Tim Illidge, Damien Huglo, et al.
Blood|March 3, 2017
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association reportMira Tout, Olivier Casasnovas, Michel Meignan, et al.
Pageof 28

Showing results (61-70 of 272) with videos related to

Sort By:
Pageof 28
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Blood Cancer Journal|August 21, 2021
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trialFranck Morschhauser, Nilanjan Ghosh, Izidore S Lossos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Hematology & Oncology|September 19, 2024
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patientsMarion Alcantara, Marion Chevrier, Fabrice Jardin, et al.
Blood Advances|April 20, 2021
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphomaCédric Ménard, Delphine Rossille, Joelle Dulong, et al.
Haematologica|January 16, 2016
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient ProgramAurore Perrot, Hélène Monjanel, Réda Bouabdallah, et al.
Blood|August 22, 2014
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN studyGuillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, et al.
Hematological Oncology|December 1, 2024
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I TrialAnna Sureda, Antonio Pinto, Hervé Ghesquières, et al.
Blood|March 28, 2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser, Tim Illidge, Damien Huglo, et al.
Blood|March 3, 2017
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association reportMira Tout, Olivier Casasnovas, Michel Meignan, et al.
Pageof 28